Aug 23, 2018
FDA approves first drug Oxervate (cenegermin) for neurotrophic keratitis, a rare eye disease
FDA approves first drug Oxervate (cenegermin) for neurotrophic keratitis, a rare eye disease
The U.S. Food and Drug Administration today approved the first drug, Oxervate (cenegermin), for the treatment of neurotrophic keratitis, a rare disease affecting the cornea (the clear layer that covers the colored portion of the front of the eye). “While the prevalence of neurotrophic keratitis is low, the impact of this serious condition on an individual patient can be devastating,” said Wiley…
View On WordPress